[HTML][HTML] A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
KA Moore, JT Ostrowsky, AM Kraigsley, AJ Mehr… - Vaccine, 2021 - Elsevier
Improved influenza vaccines are urgently needed to reduce the burden of seasonal
influenza and to ensure a rapid and effective public-health response to future influenza …
influenza and to ensure a rapid and effective public-health response to future influenza …
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …
[HTML][HTML] Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges
The development of safe and effective vaccines in a record time after the emergence of the
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a remarkable …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a remarkable …
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities.
Questions regarding the robustness, functionality and longevity of the antibody response to …
Questions regarding the robustness, functionality and longevity of the antibody response to …
Neutralizing antibody responses in COVID-19 convalescent sera
WT Lee, RC Girardin, AP Dupuis… - The Journal of …, 2021 - academic.oup.com
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an
experimental treatment for eligible patients with SARS-CoV-2 infections. The United States …
experimental treatment for eligible patients with SARS-CoV-2 infections. The United States …
[HTML][HTML] Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine
RS Thwaites, ASS Uruchurtu, VA Negri… - Nature …, 2023 - nature.com
Compared to intramuscular vaccines, nasally administered vaccines have the advantage of
inducing local mucosal immune responses that may block infection and interrupt …
inducing local mucosal immune responses that may block infection and interrupt …
[HTML][HTML] A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity
BACKGROUND To understand the features of a replicating vaccine that might drive potent
and durable immune responses to transgene-encoded antigens, we tested a replication …
and durable immune responses to transgene-encoded antigens, we tested a replication …
Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
R Goupil, M Benlarbi, W Beaubien-Souligny… - Cmaj, 2021 - Can Med Assoc
BACKGROUND: Patients receiving in-centre hemodialysis are at high risk of exposure to
SARS-CoV-2 and death if infected. One dose of the BNT162b2 SARS-CoV-2 vaccine is …
SARS-CoV-2 and death if infected. One dose of the BNT162b2 SARS-CoV-2 vaccine is …
[HTML][HTML] Randomized, double-blind, reference-controlled, phase 2a study evaluating the immunogenicity and safety of OVX836, a nucleoprotein-based influenza …
I Leroux-Roels, G Waerlop, J Tourneur… - Frontiers in …, 2022 - frontiersin.org
OVX836 is a recombinant protein-based vaccine targeting the highly conserved influenza
nucleoprotein (NP), which aims to confer a broad-spectrum protection against influenza. In a …
nucleoprotein (NP), which aims to confer a broad-spectrum protection against influenza. In a …
[HTML][HTML] Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons
Background Biological aging represents a loss of integrity and functionality of physiological
systems over time. While associated with an enhanced risk of adverse outcomes such as …
systems over time. While associated with an enhanced risk of adverse outcomes such as …